Sep. 7 at 10:15 AM
Good morning, investors. Biotech remains selective as clinical results, regulatory updates, and financial strength drive sharp company specific moves, while commodity strength suggests capital continues rotating beyond technology. Among gainers,
$GPRO surged 22% amid ongoing merger discussions, while
$VERX gained 15% as investors focused on its cancer therapy pipeline. On the downside,
$DVLT fell 25% amid legal concerns and heavy selling pressure. In movers,
$ADAS traded unusually heavy volume despite falling 3%, while
$BTBT also saw elevated activity. Read the full Analytica Alpha 👇
https://analyticainvestor.beehiiv.com/p/chips-drive-bounce-dvlt-25
